Sheet	1	of	3

			*	•								
FORM PTO-1449			O I P E U.S. Dept. of Commerce		Atty Docket No.			Serial No. 09/202,054				
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Patent and Trademark Office		Applicant Goddard et al.						
(Use several sheets if necessary)		y) EE			Filing Date 07 Dec 1998			Group 1646/1647				
TRADEFOREIGN PATENT DOCUMENTS												
Examiner Initials		Document Number	Date		Country		Class	Subclass	Transla Yes	tion No		
1	1	307,247	15.03.89	EPO						-		
H	2	WO 98/50547 -	12.11.98	PCT						.=		
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)												
Altschul et al., "Local alignment statistics" Methods in Enzymology 266:460-480 (1996)												
X	,	Bazil et al., "Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen"										
	_	European Journal of Immunology 16(12):1583-1589 (Dec 1986)										
		Belvin and Anderson, "A conserved signaling pathway: the Drosophila toll-dorsal pathway" <u>Annual Review</u> of Cell & Developmental Biology 12:393-416 (1996)										
		Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" Gene 2:95-113 (1977)										
		Croston et al., "NF-KB activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity" <u>Journal of Biological Chemistry</u> 270(28):16514-16517 (Jul 14, 1995)										
-		Dangl and Holub, "La dolce vita: a molecular feast in plant-pathogen interactions" <u>Cell</u> 91(1):17-24 (Oct 3, 1997)										
		Delude et al., "CD14-mediated translocation of nuclear factor-kappa B induced by lipopolysaccharide does not require tyrosine kinase activity" <u>Journal of Biological Chemistry</u> 269(35):22253-22260 (Sep 2, 1994)										
X.	ZEST #2243209 (LIFESEQTM, Incyte Pharmaceuticals, Palo Alto, CA)											
\times												
	11	EST #694401 (LIFE	SEQ'N, Incyte I	Pharmaceuticals	, Palo Alto, CA)	1	. \					
		EST #INC3115949 ((LIEESEO'M Inc.	te Pharmaceuti	cale Palo Alto	(Δ)	No rel	evanco				
X	12	EST #INCSITISFES ((BIFESEQ.4, Inc.)	yte Fharmateuti	cais, raio Aico,							
	13	GenBank Locus <u>HSU</u>	J79260 (Accessio	on <u>U79260)</u> (Web	page file printo	_	no date of pu	iblio availabi	(4-07)			
		SenBank Locus HSI	188540 (Accessio	on (188540) (Web	page filerprinto		or date of ac		"" ^y			
N 1 1	14	Spinoum 20000 ind	700510 (11000551	<u> </u>	The state of the s	- 1	provided, the	refore not				
		GenBank Locus HSU	J88878 (Accessio	on U88878) (Web	page file printo		considered. 11/4/09					
	15			**************************************		L.	LMS/					
\mathbb{W}	16	GenBank Locus <u>HSU</u>	J88879 (Accessio	o <u>n U&8879)</u> (Web	page file printo	ut)						
		GenBank Locus <u>HSU</u>	J88880 (Accessio	on U83880) (Web	page file printo	ut)						
	17		Market									
\sqrt{N}	18	GenBank Locus HS088881 (Accession U88881) (Web page file printout)										
	19	Genbank Locus HUM	MRSC786 (Access	ion D13637) (We	b page file print	out)						
Examine					Da	ate Cons	idered					
*Examiner: Initial It reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation If not in conformance and not considered. Include copy of this form with next communication to applicant.												

Paper#6

USCOMM-DC 80-398.